Carbenicillin
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Carbenicillin: From Gram-Negative Bacterial Infections to Ureaplasma Urethritis
One-Sentence Summary
Carbenicillin is a broad-spectrum, extended-spectrum penicillin (β-lactam class) antibiotic historically used against gram-negative bacterial infections, including Pseudomonas aeruginosa and urinary tract pathogens. The TxGNN model predicts it may be effective for Ureaplasma Urethritis; however, 0 clinical trials and 0 publications support this direction, and the prediction is mechanistically implausible — Ureaplasma completely lacks a cell wall, making it intrinsically resistant to all β-lactam antibiotics.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gram-negative bacterial infections (historical; no India regulatory records found) |
| Predicted New Indication | Ureaplasma Urethritis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, Carbenicillin is a broad-spectrum extended-spectrum penicillin that inhibits bacterial cell wall synthesis by binding to Penicillin-Binding Proteins (PBPs) — particularly PBP2 — disrupting peptidoglycan cross-linking and leading to osmotic lysis. Historically, it demonstrated activity against Pseudomonas aeruginosa, Escherichia coli, Proteus species, and other aerobic gram-negative organisms.
This prediction is, however, mechanistically untenable. Ureaplasma urealyticum belongs to the class Mollicutes and completely lacks a cell wall — there is no peptidoglycan layer and no PBPs present. This constitutes absolute, intrinsic resistance to every β-lactam antibiotic, including Carbenicillin. No dose optimization or formulation change can overcome this biological structural reality; the drug’s target simply does not exist in this pathogen.
The high TxGNN score (99.98%) most likely reflects disease-node similarity within the knowledge graph: both Ureaplasma urethritis and Carbenicillin’s established indications cluster within the “urogenital infection” disease space. This is a graph topology artifact — a proximity signal — rather than a genuine antibacterial activity prediction. This result should be treated as a false positive and does not warrant clinical development.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Drug Interactions — 18 interactions identified (DDInter database):
| Interacting Drug | Severity | Clinical Relevance |
|---|---|---|
| Methotrexate | Major | Penicillins compete with methotrexate for renal tubular secretion, potentially causing methotrexate toxicity (myelosuppression, mucositis) |
| Warfarin | Moderate | Broad-spectrum antibiotics alter gut flora, reducing Vitamin K synthesis and potentially enhancing anticoagulant effect |
| Dicoumarol | Moderate | Same mechanism as Warfarin interaction |
| Pemetrexed | Moderate | Reduced renal clearance may increase Pemetrexed plasma exposure |
| Mycophenolic acid | Moderate | Antibiotics may disrupt enterohepatic recirculation, reducing immunosuppressant efficacy |
| Ethinylestradiol | Moderate | Broad-spectrum antibiotics may reduce oral contraceptive efficacy via gut flora disruption |
| Doxycycline | Moderate | Bacteriostatic tetracyclines may antagonize the bactericidal activity of penicillins |
| Tetracycline | Moderate | Bacteriostatic antagonism |
| Minocycline | Moderate | Bacteriostatic antagonism |
| Demeclocycline | Moderate | Bacteriostatic antagonism |
| Oxytetracycline | Moderate | Bacteriostatic antagonism |
| Chloramphenicol | Moderate | Bacteriostatic antagonism of penicillin activity |
| Balsalazide | Moderate | Antibiotic-mediated gut flora changes may alter balsalazide conversion |
| Picosulfuric acid | Moderate | Antibiotics may interfere with bowel preparation activation |
| Iodide I-131 | Moderate | Antibiotic-class interaction |
| Iodide I-123 | Moderate | Antibiotic-class interaction |
| Clarithromycin | Minor | Possible pharmacodynamic interaction |
| Erythromycin | Minor | Possible pharmacodynamic interaction |
Conclusion and Next Steps
Decision: Hold
Rationale: Ureaplasma urealyticum is a naturally cell-wall-deficient organism for which all β-lactam antibiotics are fundamentally inactive by mechanism. The TxGNN score of 99.98% reflects urogenital disease-node clustering in the knowledge graph rather than any real biological activity, and there is zero supporting clinical or preclinical evidence. Pursuing this indication would be scientifically unsound.
Note on Other Predicted Indications: Across the full set of 7 TxGNN predictions for Carbenicillin, the only indication with meaningful clinical evidence is Gonococcal Urethritis (Rank 2, L3) — 4 historical publications (1972–2001) directly document Carbenicillin’s use against Neisseria gonorrhoeae via PBP2 inhibition. However, this also faces major barriers: modern N. gonorrhoeae is predominantly penicillin-resistant (PPNG strains), WHO no longer recommends penicillin-class antibiotics for gonorrhea, and Carbenicillin has been withdrawn from most markets. The remaining 5 predicted indications (uterine inflammatory disease, xanthogranulomatous pyelonephritis, urogenital tuberculosis, epiglottitis, laryngitis) are all rated L4–L5 with Hold recommendations, ranging from incomplete coverage to mechanistic impossibility (TB).
To proceed, the following is needed:
- Mechanistic justification review: confirm whether any predicted indication has a valid β-lactam–sensitive pathogen as primary etiology
- For gonococcal urethritis specifically: obtain current PPNG prevalence data in the target population to assess residual susceptibility
- Obtain the TFDA/CDSCO package insert (or equivalent historical labeling) to fill the Blocking data gap on warnings and contraindications before any safety evaluation
- Regulatory pathway assessment for a drug that has been withdrawn from most major markets
- Evaluate whether updated formulations (e.g., oral Carbenicillin indanyl sodium) could be sourced or reformulated if any indication proceeds
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.